VERTEX FIRST-QUARTER 2021 FINANCIAL RESULTS APRIL 29, 2021 ©2021 Vertex Pharmaceuticals Incorporated global.vrtx.com AGENDA Introduction Michael Partridge, Senior Vice President, Investor Relations CEO Perspective and R&D Update Reshma Kewalramani, M.D., CEO and President Commercial Update Stuart Arbuckle, Executive Vice President and Chief Commercial and Operations Officer Financial Results Charlie Wagner, Executive Vice President and Chief Financial Officer ©2021 Vertex Pharmaceuticals Incorporated global ...

(Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K For the transition period from to Commission File Number: 333-239644 VERTEX, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | | 23-2081753 | | --- | --- | ...

Vertex, Inc. (NASDAQ:VERX) Q4 2020 Earnings Conference Call March 10, 2021 8:30 AM ET Company Participants Ankit Hira – Investor Relations David DeStefano – Chief Executive Officer John Schwab – Chief Financial Officer Conference Call Participants Brad Reback – Stifel Daniel Jester – Citigroup Brad Sills – Bank of America Securities Pat Walravens – JMP Group Chris Merwin – Goldman Sachs Stan Zlotsky – Morgan Stanley Bhavan Suri – William Blair Jordan Bret – Jefferies Josh Reilly – Needham & Company Operator ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) For the transition period from to Commission File Number: 333-239644 VERTEX, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 23-2081753 | | --- ...

Vertex, Inc. (NASDAQ:VERX) Q3 2020 Earnings Conference Call November 11, 2020 8:30 AM ET Company Participants Ankit Hira - Investor Relations David DeStefano - Chief Executive Officer John Schwab - Chief Financial Officer Conference Call Participants Brad Sills - Bank of America Samad Samana - Jefferies Brad Reback - Stifel Pat Walravens - JMP Group Chris Merwin - Goldman Sachs Stan Zlotsky - Morgan Stanley Bhavan Suri - William Blair Daniel Jester - Citi Operator Good morning and welcome to Vertex’s Third ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-239644 VERTEX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 23-2081753 (State or other jurisdiction of inc ...

Vertex, Inc. (NASDAQ:VERX) Q2 2020 Earnings Conference Call September 9, 2020 8:30 AM ET Company Participants Ankit Hira - IR David DeStefano - CEO, President & Chairman John Schwab - CFO Conference Call Participants Samad Samana - Jefferies Brad Sills - Bank of America Merrill Lynch Chris Merwin - Goldman Sachs Group Stan Zlotsky - Morgan Stanley Brad Reback - Stifel, Nicolaus & Company Pat Walravens - JMP Securities Bhavan Suri - William Blair & Company Daniel Jester - Citigroup Operator Greetings. Welcom ...